TRVI vs. HRMY, ARQT, JANX, TVTX, AGIO, TARS, APGE, VERA, IRON, and SDGR
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Vera Therapeutics (VERA), Disc Medicine (IRON), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs.
Trevi Therapeutics (NASDAQ:TRVI) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Trevi Therapeutics received 41 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 70.33% of users gave Harmony Biosciences an outperform vote while only 67.74% of users gave Trevi Therapeutics an outperform vote.
Harmony Biosciences has a net margin of 17.98% compared to Trevi Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 23.16% beat Trevi Therapeutics' return on equity.
Trevi Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Harmony Biosciences has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Trevi Therapeutics currently has a consensus price target of $17.56, indicating a potential upside of 170.40%. Harmony Biosciences has a consensus price target of $53.33, indicating a potential upside of 60.79%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Trevi Therapeutics is more favorable than Harmony Biosciences.
In the previous week, Trevi Therapeutics had 21 more articles in the media than Harmony Biosciences. MarketBeat recorded 35 mentions for Trevi Therapeutics and 14 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 0.87 beat Trevi Therapeutics' score of 0.19 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Summary
Harmony Biosciences beats Trevi Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy TRVI Stock Free TRVI Stock Alerts